Results 141 to 150 of about 84,996 (200)

Detection of nirsevimab-resistant RSV-B variants in children carrying the F:N201T substitution through genomic surveillance, Spain, 2025/26 season. [PDF]

Euro Surveill
Iglesias-Caballero M, Infantes JA, Campoy A, Camarero-Serrano S, Moreno S, Cano O, Vallejo-Palma G, González-Velasco C, Gaona C, Camacho-Martinez P, Merino-Diaz L, Vázquez-Morón S, Pozo F, Lepe JA, Mas V, Casas I.   +15 more
europepmc   +1 more source

Respiratory Syncytial Virus Vaccine Effectiveness Among US Older Adults, 2023-2024 Season.

JAMA Netw Open
Lu Y, Smith ER, McEvoy R, Spencer MRT, Lindaas AF, Izurieta HS, Zhang Y, Zhang HT, Wagner E, Menis M, Naik NM, Steele WR, Wernecke M, Chillarige Y, Anderson SA, Forshee RA.   +15 more
europepmc   +1 more source

First Report on Remdesivir Use for the Treatment of Respiratory Syncytial Virus in Five Allogeneic Hematopoietic Cell Transplant Recipients. [PDF]

J Infect Dis
McCulloch DJ, Khawaja F, Tverdek FP, Ford ES, Vora SB, Waghmare A, Vuong N, Chemaly RF, Hill JA.   +8 more
europepmc   +1 more source

RSV Monoclonal Antibody Implementation for At-Risk Infants: Victoria, Australia's 2024 Experience. [PDF]

Health Sci Rep
Tuckerman J, Cheng DR, Hunter G, Elia S, Hearn T, Verma D, Jacobs S, Carr J, Crawford NW.   +8 more
europepmc   +1 more source

Clesrovimab in Infants at Increased Risk For Severe Disease During 2 RSV Seasons: A Randomized Clinical Trial.

JAMA Pediatr
Zar HJ, Bont LJ, Manzoni P, Muñoz FM, Ramilo O, Chen PY, Novoa JM, Ordoñez GA, Tsolia M, Tapiéro B, Acuña-Ávila MI, Castellanos JM, Meyer M, Morioka I, Heinonen S, Chen Z, Zeng T, Railkar RA, Arriola CS, Zang X, Hildebrand C, Maestri A, Castagnini LA, Sinha A, SMART (MK-1654-007) study group.   +24 more
europepmc   +1 more source

Evaluation of Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV/ΔNS2/Δ1313/I1314L and RSV/276 in RSV-Seronegative Children. [PDF]

Journal of Infectious Diseases, 2022
Abstract Background This United States-based study compared 2 candidate vaccines: RSV/ΔNS2/Δ1313/I1314L, attenuated by NS2 gene-deletion and temperature-sensitivity mutation in the polymerase gene; and RSV/276, attenuated by M2-2 deletion. Methods
Matthew S Kelly, Mary Paul, Coleen Cunningham   +2 more
exaly   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

Predicting the RSV Surge: Pediatric RSV Patterns of the COVID Pandemic

Pediatric Infectious Disease Journal, 2023
Historically, respiratory syncytial virus (RSV) infection trends have been predictable. The COVID-19 pandemic and associated precautions impacted RSV disease patterns. RSV infection trends during the first year of the COVID-19 pandemic may have predicted the 2022 surge in pediatric RSV infections.
Sidney Zven, Madeline Dorr, Allison M. W. Malloy, Apryl Susi, Cade M. Nylund, Elizabeth Hisle-Gorman   +5 more
openaire   +2 more sources

Health economics and RSV

Paediatric Respiratory Reviews, 2009
An economic analysis was performed in Spain to evaluate the efficiency (cost-effectiveness) of palivizumab in preventing severe RSV infection in premature infants with GA 32-35 and two or more risk factors (RF). The design was a decision tree model using data from the scientific literature and the FLIP I and FLIP II studies IRIS Study Group.
Xavier, Carbonell-Estrany, Pablo, Lázaro y de Mercado   +1 more
openaire   +2 more sources